PTC Therapeutics Enters into Agreement to Sell Priority Review Voucher for $150 Million

Core Viewpoint - PTC Therapeutics, Inc. has announced an agreement to sell its Rare Pediatric Disease Priority Review Voucher for $150 million, contingent upon the closing of the transaction [1][2]. Group 1: Transaction Details - The Rare Pediatric Disease Priority Review Voucher was granted to PTC on November 13, 2024, alongside FDA approval for KEBILIDI™ for treating AADC deficiency [2]. - The transaction is subject to customary closing conditions, including the expiration of the applicable waiting period under the Hart-Scott Rodino Antitrust Improvements Act [2]. Group 2: About the PRV Program - The FDA awards priority review vouchers to sponsors of rare pediatric disease product applications that meet specific criteria, aimed at encouraging the development of new drugs for rare pediatric diseases [3]. Group 3: Company Overview - PTC Therapeutics is a global biopharmaceutical company focused on discovering, developing, and commercializing clinically differentiated medicines for rare disorders [4]. - The company aims to provide access to best-in-class treatments for patients with limited treatment options, leveraging its scientific expertise and global commercial infrastructure [4].